Evidence map›Paper›PMID 27409812›Full record

ArticleNature2016

Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.

Dean P Staus, Ryan T Strachan, Aashish Manglik, Biswaranjan Pani, Alem W Kahsai, Tae Hun Kim, Laura M Wingler, Seungkirl Ahn, Arnab Chatterjee, Ali Masoudi and 8 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed
24.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 327 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Biased Allosteric Modulation in GPCR Drug Discovery.Handbook of experimental pharmacology · 2026
    Review
  10. Review
  11. Nanobodies targeting hnRNPA2/B1 and tau.bioRxiv : the preprint server for biology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 4 countries.

Dean P Staus
Ryan T Strachan
Aashish Manglik
Biswaranjan Pani
Alem W Kahsai
Tae Hun Kim
Laura M Wingler
Seungkirl Ahn
Arnab Chatterjee
Ali Masoudi
Andrew C Kruse
Els Pardon
Jan Steyaert
William I Weis
R Scott Prosser
Brian K Kobilka
Tommaso Costa
Robert J Lefkowitz
Duke Medical Center · USDuke University Hospital · USStanford University · USUniversity of Toronto · CAVrije Universiteit Brussel · BEHarvard University · USHoward Hughes Medical Institute · USIstituto Superiore di Sanità · ITUniversity of North Carolina at Chapel Hill · US

Funding

Molecular Regulation of Cardiovascular 7 TM ReceptorsR01HL016037 · NHLBI · DUKE UNIVERSITY · PI ROBERT J LEFKOWITZ · 1985 to 2026
$14.5M
MULTIDISCIPLINARY HEART &VASCULAR DISEASEST32HL007101 · NHLBI · DUKE UNIVERSITY · PI FREEDMAN, NEIL J. · 1985 to 2020
$9.8M
Molecular Biophysics Training Program at StanfordT32GM008294 · NIGMS · STANFORD UNIVERSITY · PI HUANG, KERWYN C. · 1989 to 2019
$7.4M
THE MECHANISM OF BETA2 ADRENOCEPTOR ACTIVATIONR01NS028471 · NINDS · STANFORD UNIVERSITY · PI KOBILKA, BRIAN K · 1990 to 2021
$6.7M
Beta2 Adrenoceptor Structure and Mechanism of ActivationR37NS028471 · NINDS · STANFORD UNIVERSITY · PI KOBILKA, BRIAN K · 2005 to 2011
$3.9M
DUKE TRAINING GRANT IN NEPHROLOGYT32DK007731 · NIDDK · DUKE UNIVERSITY · PI CROWLEY, STEVEN D · 1995 to 2021
$3.6M
B-Arrestins and G Protein-Coupled Receptor Kinases in Cardiovascular FunctionR01HL070631 · NHLBI · DUKE UNIVERSITY · PI LEFKOWITZ, ROBERT J · 2002 to 2011
$3.5M
MOLECULAR PROPERTIES OF CARDIAC ADRENERGIC RECEPTORSR37HL016037 · NHLBI · DUKE UNIVERSITY · PI LEFKOWITZ, ROBERT J · 1986 to 1995
–
Howard Hughes Medical InstituteNHLBI NIH HHS HL16037NHLBI NIH HHS HL70631NHLBI NIH HHS R01 HL016037NHLBI NIH HHS R01 HL070631NHLBI NIH HHS T32 HL007101NHLBI NIH HHS T32HL007101NIDDK NIH HHS T32 DK007731NIGMS NIH HHS T32 GM008294NINDS NIH HHS NS028471NINDS NIH HHS R01 NS028471NINDS NIH HHS R37 NS028471
6 · The paper itself

Abstract

G-protein-coupled receptors (GPCRs) modulate many physiological processes by transducing a variety of extracellular cues into intracellular responses. Ligand binding to an extracellular orthosteric pocket propagates conformational change to the receptor cytosolic region to promote binding and activation of downstream signalling effectors such as G proteins and β-arrestins. It is well known that different agonists can share the same binding pocket but evoke unique receptor conformations leading to a wide range of downstream responses (‘efficacy’). Furthermore, increasing biophysical evidence, primarily using the β2-adrenergic receptor (β2AR) as a model system, supports the existence of multiple active and inactive conformational states. However, how agonists with varying efficacy modulate these receptor states to initiate cellular responses is not well understood. Here we report stabilization of two distinct β2AR conformations using single domain camelid antibodies (nanobodies)—a previously described positive allosteric nanobody (Nb80) and a newly identified negative allosteric nanobody (Nb60). We show that Nb60 stabilizes a previously unappreciated low-affinity receptor state which corresponds to one of two inactive receptor conformations as delineated by X-ray crystallography and NMR spectroscopy. We find that the agonist isoprenaline has a 15,000-fold higher affinity for β2AR in the presence of Nb80 compared to the affinity of isoprenaline for β2AR in the presence of Nb60, highlighting the full allosteric range of a GPCR. Assessing the binding of 17 ligands of varying efficacy to the β2AR in the absence and presence of Nb60 or Nb80 reveals large ligand-specific effects that can only be explained using an allosteric model which assumes equilibrium amongst at least three receptor states. Agonists generally exert efficacy by stabilizing the active Nb80-stabilized receptor state (R80). In contrast, for a number of partial agonists, both stabilization of R80 and destabilization of the inactive, Nb60-bound state (R60) contribute to their ability to modulate receptor activation. These data demonstrate that ligands can initiate a wide range of cellular responses by differentially stabilizing multiple receptor states.

Indexed as

Adrenergic beta-2 Receptor AgonistsAllosteric RegulationAllosteric SiteCrystallography, X-RayDrug Partial AgonismHumansIsoproterenolLigandsModels, MolecularNuclear Magnetic Resonance, BiomolecularProtein ConformationProtein StabilityReceptors, Adrenergic, beta-2Single-Domain AntibodiesAdrenergic beta-2 Receptor AgonistsIsoproterenolLigandsReceptors, Adrenergic, beta-2Single-Domain Antibodies

Identifiers

PMID27409812
PMCPMC4961583
OpenAlexW2471992026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.